Ponatinib has been shown to be highly effective in heavily pretreated CML* patients or certain ALL** patients who are resistant or intolerant to Sprycel (dasatinib) or Tasigna (nilotinib) or have the T3151*** mutation and has been submitted to the FDA for approval with a request for priority review.
*CML - chronic myelogenous leukemia
**ALL - acute lymphocytic leukemia
***T3151 mutation - a genetic mutation in some forms of leukemia which causes resistance to some drugs.
http://www.chemotherapyadvisor.com/ponatinib-active-in-patients-with-cml-and-ph-all-resistantintolerant-to-dasatinib-or-nilotinib-or-who-have-the-t315i-mutation/article/260399/?DCMP=EMC-CTA_Front&Visitor_ID=&cpn=cta_sutinl&spMailingID=4840653&spUserID=MTM2NzY5NTE2MDgS1&spJobID=53829863&spReportId=NTM4Mjk4NjMS1
No comments:
Post a Comment